| Clinical data | |
|---|---|
| Other names | SYT510 |
| Routes of administration | Oral |
| Drug class | Endocannabinoid reuptake inhibitor |
SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders. It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target. As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications. It is under development by a pharmaceutical company called Synendos Therapeutics.
References
- ^ "Delving into the Latest Updates on SYT-510 with Synapse". Synapse. 4 August 2024. Retrieved 15 August 2024.
- ^ "SYT 510". AdisInsight. 22 January 2024. Retrieved 15 August 2024.
- ^ Gertsch J, Chicca A (July 2024). "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem: e202400397. doi:10.1002/cbic.202400397. PMID 38958639.
Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the with SERIs to enable restoration of the natural functioning of the brain.
- ^ Therapeutics, Synendos (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". PR Newswire. Retrieved 15 August 2024.
External links
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |